OSI Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Global Markets Direct
November 28, 2011
113 Pages - SKU: GMD6692804
OSI Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “OSI Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the OSI Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, OSI Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from OSI Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • OSI Pharmaceuticals, Inc. - Brief OSI Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of OSI Pharmaceuticals, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of OSI Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the OSI Pharmaceuticals, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate OSI Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of OSI Pharmaceuticals, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the OSI Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with OSI Pharmaceuticals, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of OSI Pharmaceuticals, Inc. and identify potential opportunities in those areas.



More Pharmaceuticals Company reports by Global Markets Direct

NeuroNascent, Inc. - Product Pipeline Review - 2014 by Global Markets Direct
NeuroNascent, Inc. - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘NeuroNascent, Inc. - Product Pipeline Review - 2014’, provides an overview of the NeuroNascent, Inc.’s ...
Mabion SA - Product Pipeline Review - 2014 by Global Markets Direct
Mabion SA - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘Mabion SA - Product Pipeline Review - 2014’, provides an overview of the Mabion SA’s ...
Lipocine Inc. - Product Pipeline Review - 2014 by Global Markets Direct
Lipocine Inc. - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘Lipocine Inc. - Product Pipeline Review - 2014’, provides an overview of the Lipocine Inc.’s ...
Xenon Pharmaceuticals Inc. - Product Pipeline Review - 2014 by Global Markets Direct
Xenon Pharmaceuticals Inc. - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘Xenon Pharmaceuticals Inc. - Product Pipeline Review - 2014’, provides an overview of the ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 500  
    Global Site License  USD 1,500  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!